CA
NZ
UK
AU
IND
US
Actuate Therapeutics (NASDAQ: ACTU) suffered a sharpReversalon Tuesday, declining 11.82 per cent to $2.91, in what may rank as one of the more counterintuitive market reactions of the day. The company had just announced that the US Food and Drug Administration had cleared its …
Galectin Therapeutics (NASDAQ: GALT) rose 6.67 per cent to $2.24 on Tuesday after the publication of its Phase 2b NAVIGATE trial results in Hepatology, one of the field's most respected peer-reviewed journals. The data — assessing belapectin in patients with metabolic dysfunction-associated steatohepatitis cirrhosis …
Moderna (NASDAQ: MRNA) gave back ground on Tuesday, declining 3.59 per cent to $52.40, even as the company found itself at the centre of an emerging outbreak narrative that has placed hantavirus — rarely a name that registers with mainstream investors — into the …
Aditxt, Inc. (NASDAQ: ADTX) plunged nearly 15 per cent on Tuesday to $0.1010, as shareholders absorbed the implications of a Nasdaq Staff Determination letter that brought the company to the edge of a potentially terminal regulatory cliff. The disclosure confirmed what the share price …
Longeveron Inc. (NASDAQ: LGVN) barely moved on Tuesday, edging up just 0.59 per cent to $0.8502, in a muted market response to a regulatory development that, in a different sentiment environment, might have been expected to hit the stock considerably harder. The company disclosed …
A rodent-borne pathogen that rarely attracts mainstream financial attention is now driving material moves in aNasdaq-listed biotech. Traws Pharma (NASDAQ: TRAW) announced on May 8, 2026, plans to identify and advance clinical candidates targeting hantavirus infections. Shares closed up 28% at USD 2.18, extending …
A hantavirus outbreak that began quietly in the South Atlantic has now reached American soil, reigniting market interest in infectious disease countermeasures and placing a little-known rodent-borne pathogen under mainstream financial scrutiny.
Pharming Group, the Netherlands-based rare disease specialist best known for RUCONEST — its recombinant C1 esterase inhibitor for hereditary angioedema — issued full-year 2026 revenue guidance of $405 million to $425 million on Friday, a range that straddled analyst consensus of $411.9 million but …
Atara Biotherapeutics received perhaps the most consequential piece of regulatory clarity in its corporate history on Friday, as the US Food and Drug Administration confirmed — following a Type A meeting — that a single-arm study supported by an appropriate historical control could serve …
Entrada Therapeutics reported what it described as a statistically significant and potentially differentiated improvement versus placebo in Time to Rise velocity from its Phase 1/2 ELEVATE-44-201 trial of ENTR-601-44 in patients with Duchenne muscular dystrophy carrying exon 44-amenable mutations — and watched its shares …
Please wait processing your request...